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Abstract
Purpose: The immune response is crucial in the development of multi-organ failure (MOF) and complications in end-stage
heart failure patients supported by left ventricular assist device (LVAD). However, at pre-implant, the association between
inflammatory state and post-LVAD outcome is not yet clarified. Aim of the study was to assess the relationship among pre-
implant levels of immune-related cytokines, postoperative inflammatory response and 3-month outcome in LVAD-patients.
Methods: In 41 patients undergoing LVAD implantation, plasma levels of interleukin (IL)-6, IL-8, crucial for monocyte
modulation, and urine neopterin/creatinine ratio (Neo/Cr), marker of monocyte activation, were assessed preoperatively, at
3 days, 1 and 4 weeks post-LVAD. MOF was evaluated by total sequential organ failure assessment (tSOFA) score. Intensive
care unit (ICU)-death and/or post-LVAD tSOFA $11 was considered as main adverse outcome. Length of ICU-stay, 1 week-
tSOFA score, hospitalisation and 3-month survival were considered additional end-points.
Results: During ICU-stay, 8 patients died of MOF, while 8 of the survivors experienced severe MOF with postoperative tSOFA
score $11. Pre-implant level of IL-6 $ 8.3 pg/mL was identified as significant marker of discrimination between patients
with or without adverse outcome (OR 6.642, 95% CI 1.201-36.509, p= 0.030). Patients were divided according to pre-implant
IL-6 cutoff of 8.3 pg/ml in A [3.5 (1.2–6.1) pg/mL] and B [24.6 (16.4–38.0) pg/mL] groups. Among pre-implant variables, only
white blood cells count was independently associated with pre-implant IL-6 levels higher than 8.3 pg/ml (OR 1.491, 95% CI
1.004–2.217, p= 0.048). The ICU-stay and hospitalisation resulted longer in B-group (p= 0.001 and p= 0.030, respectively).
Postoperatively, 1 week-tSOFA score, IL-8 and Neo/Cr levels were higher in B-group.
Conclusions: LVAD-candidates with elevated pre-implant levels of IL-6 are associated, after intervention, to higher release of
monocyte activation related-markers, a clue for the development of MOF, longer clinical course and poor outcome.
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Introduction
In an era characterised by lack of suitable organs for
transplantation, continuous flow left ventricular assist devices
(CF-LVADs) bridge patients with end-stage heart failure (ESHF)
to transplantation (BTT), to further decision (BTD), or to
recovery, or are implanted as destination therapy (DT) [1–3].
Despite progressive improvements in technologies, intraoperative
and perioperative management, favourable outcomes still depend
on proper patient selection and strategic timing of implantation.
Indications, absolute or relative contraindications are not univer-
sally accepted and contrasting data have been published [1–4].
With worsening of clinical status of ESHF patients, increase the
need for a mechanical circulatory support (MCS) as the peri-
operative risk, resulting in a greater exertion in managing the
timing of implant [1–4]. Indeed, in many centers, LVAD
implantation is anticipated, preferably before that the patient
experiences hemodynamic collapse [5].
Adverse outcomes and development of multi-organ failure
(MOF) in LVAD-patients are related to the activation of systemic
inflammation, although mechanisms underlying the multi-organ
deterioration remain still poorly understood [6]. The levels of
interleukin (IL)-6 and IL-8, crucial cytokines for the activation of
systemic inflammatory pathways, and neopterin, a marker
reflecting monocyte activation, are found to increase after LVAD
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implantation, particularly in patients affected by MOF [7], the
main cause of death during the early phase of MCS [8]. Moreover,
pre-implant levels of IL-6 have been associated with hemodynamic
status, as defined by Interagency Registry for Mechanically
Assisted Circulatory Support (INTERMACS) profiles, with higher
levels in patients presenting critical INTERMACS profiles [9].
Since the signal pathways, IL-6-dependent, and specific monocyte
attracting chemokines, such as IL-8, are proposed as crucial
triggers in controlling monocyte activation, an important condi-
tion in the development of MOF and of haemostatic complications
[10], it can be assumed that they play a critical role in affecting
outcomes during the early phase of LVAD support. The aims of
this study were to assess whether preoperative IL-6, IL-8 and
neopterin levels affect postoperative inflammatory response and
short-term (3 months) outcomes in LVAD-recipients.
Methods
Patients
From January 2005 to February 2012, 56 VAD implantations
have been performed in ESHF-patients at our institution. Nothing
was changed in our VAD peri-operative management protocol
along these years. Patients with a diagnosis of myocarditis or
undergoing MCS with a short term device (intra aortic balloon
pump, Impella Recover, peripheral or intra-thoracic extracorpo-
real membrane oxygenation), with a pulsatile or biventricular
VAD were excluded as well as patients undergoing concomitant
cardiac procedures. One patient listed for a long-term CF-LVAD,
requiring unplanned extra-corporeal membrane oxygenation
(ECMO) support for sudden circulatory failure before LVAD
support, was included. Patients with acute cardio-circulatory
failure, treated with ECMO as BTD and later treated with
complex devices (long-term, intra-corporeal, continuous axial or
centrifugal flow LVADs), were not included.
Forty-one patients complying the selection criteria according to
guideline indications for mechanical support [11], were definitively
enrolled for this study.
Twenty chronic HF (CHF) patients, matched for age, sex,
diagnosis and NYHA classes with LVAD-candidates, were
enrolled to compare the cytokine levels between chronic state
and end-stage of HF disease.
Ethics Statement
This study complied with the principles of the Declaration of
Helsinki. The study protocol has been approved by the Ethics
Committee of Niguarda Ca’ Granda Hospital (Milan, Italy) and a
signed informed consent has been obtained by all participating
patients.
Study design and assays
Baseline demographics, operative characteristics and postoper-
ative details were collected for all patients. Trans-thoracic and or
trans-esophageal echocardiography was pre-operatively per-
formed. Hemodynamic data were assessed pre-operatively and
then daily, up to a maximum of 1 week, by means of a pulmonary
artery Swan-Ganz catheter. MOF was monitored pre-operatively
and up to a maximum of 2 weeks calculating the total Sequential
Organ Failure Assessment (tSOFA) score. The SOFA system, used
for predicting intensive care unit (ICU)-mortality [12], is a daily
score from 0 to 4 assigned in proportion to the severity of
functional deterioration for each of 6 individual organ systems
(cardiovascular, respiratory, hepatic, renal, neurologic, and
hemocoagulative). The tSOFA score was calculated by adding
the scores for each of the organ systems during the first post-
operative weeks [12].
After the operation, right heart dysfunction was diagnosed in
the presence of inotropic equivalent .10 and/or right atrial
pressure .10 mm Hg [13]. Renal function was assessed by
estimated glomerular filtration rate using the abbreviated MDRD
formula [14].
The combination of postoperative tSOFA score $11 [15] and/
or ICU-death was taken into account as main composite adverse
outcome.
The following end-points were also considered: tSOFA score at
1 week, length of ICU stay, hospitalisation, and 3-month survival.
Inflammatory parameters
In LVAD-patients, plasma IL-6, IL-8 levels, and urine
neopterin levels, a known marker of monocyte activation [16],
were measured pre-operatively and at 3, 7 and 30 days after
intervention. In all patients, the blood and urine samples were
collected pre-operatively in a range limited to 24 hours before
cardiopulmonary bypass induction. Plasma IL-6 and IL-8 levels
were measured according to the method of the manufacturer of
the enzyme-linked immunosorbent assays (R&D Systems, Minne-
apolis, MN), whereas urinary neopterin levels were measured by
an isocratic HPLC method as previously described and normal-
ized by the urine creatinine concentrations as neopterin/creatinine
(Neo/Cr) ratio [6].
Statistical Analysis
Data are expressed as median and interquartile range (I-III) or
frequency (percentage).
Receiver-operating characteristics (ROC) curve and the area
under curve (AUC) was performed to determine the best cut-off
that discriminate patients with or without adverse outcome. The
associations between composite outcome, categorical IL-6 variable
and clinical or biochemical parameters was assessed by univariable
logistic regression analysis; significant variables (p,0.10) were then
entered into a multivariable logistic regression model. Results are
presented as odds ratio (OR) and their 95% confidence interval
(CI). Differences between groups were assessed by Student T test
or nonparametric Mann-Whitney test for continuous variables and
by Chi-square or Fisher exact test for categorical variables.
Differences of time-course of biochemical and clinical variables
between groups were assessed by nonparametric Friedman test
followed by Wilcoxon post-hoc test. A two-tailed p-value ,0.05
was considered statistically significant.
Results
Patient characteristics and postoperative outcome
Clinical data of candidates to LVAD implantation and
operative characteristics are described in Table 1. Twenty-five
patients were treated for a dilated cardiomyopathy. Twenty-eight
patients were in NYHA class IV, while the other patients were in
NYHA class III. Preoperative intravenous inotropes were used in
25 patients while intra-aortic balloon pump in 13. CF-LVADs
were implanted in 35 patients as BTT, in 3 patients as BTD and in
3 patients as DT.
Twenty-six (63%) patients were implanted with HeartMate II
LVADs (Thoratec, Pleasanton, CA), 8 (20%) with De Bakey
LVADs (MicroMed Technology, Houston, TX), 6 (15%) with
Incor LVADs (Berlin Heart AG, Germany), and 1 (2%) with
HeartWare LVAD (HeartWare, Framingham, MA).
After 1 week on MCS, hemodynamic improvement was
observed in all patients with increase of cardiac index [1.7 (1.4–
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Table 1. Univariable logistic regression analysis of variables associated to patient group with composite adverse outcome.
All Cases Without composite outcome
With composite
outcome P
(n = 41) (n =25) (n =16)
Age, yrs 55 (47–61) 54 (46–58) 56 (47–64) 0.267
Male gender, n (%) 37 (90) 24 (96) 13 (81) 0.155
Etiology, n (%) 0.873
IDC 25 (61) 15 (60) 10 (63)
ICM 16 (39) 10 (40) 6 (37)
NYHA class, n (%) 0.960
III 13 (32) 8 (32) 5 (31)
IV 28 (68) 17 (68) 11 (69)
INTERMACS, n (%)
1 11 (27) 6 (24) 5 (31) (Reference)
2 9 (22) 6 (24) 3 (19) 0.583
3+4 21 (51) 13 (52) 8 (50) 0.688
Pre-implant data
LVEF, % 22 (18–25) 23 (18–25) 20 (18–25) 0.263
LVEDV, ml 260 (188–315) 260 (190–330) 248 (175–304) 0.426
LVEDD, mm 70 (64–77) 70 (64–78) 66 (64–76) 0.274
CI, L/min/m2 1.68 (1.37–2.02) 1.76 (1.53–2.10) 1.49 (1.33–1.72) 0.110
RAP, mmHg 6 (4–10) 5 (3–6) 9 (5–14) 0.035
PCWP, mmHg 26 (18–30) 24 (15–30) 28 (24–33) 0.186
MAP, mmHg 75 (69–83) 78 (71–84) 73 (68–82) 0.373
Treatments, n (%)
ACEi+ATII 29 (74) 18 (75) 11 (73) 0.908
Beta-Blocker 24 (65) 16 (70) 8 (57) 0.445
Statins 12 (32) 7 (32) 5 (33) 0.923
Diuretics 32 (82) 20 (83) 12 (80) 0.792
Inotropic 25 (61) 15 (60) 10 (67) 0.923
Inotropic equivalent, n 8 (3–10) 8 (3–10) 8 (4–12) 0.816
IABP, n (%) 13 (32) 7 (28) 6 (38) 0.525
INR 1.20 (1.08–1.38) 1.12 (1.03–1.30) 1.21 (1.15–1.42) 0.370
WBC, 109/L 8.4 (6.5–10.4) 8.7 (7.1–11.5) 8.2 (5.7–8.7) 0.308
Lactate, nmol/l 1.00 (0.75–1.65) 1.00 (0.70–1.60) 1.00 (0.78–1.88) 0.402
eGFR, ml/min/1.73 m2 80 (58–107) 85 (75–114) 64 (49–83) 0.109
Total bilirubine, mg/dl 0.88 (0.60–1.44) 0.76 (0.53–1.73) 1.05 (0.61–1.68) 0.265
tSOFA score, n 5.0 (2.5–6.0) 4.0 (2.0–5.0) 5.0 (3.5–6.0) 0.078
Neo/Cr, mmoL/mol 290 (183–563) 274 (171–436) 366 (231–632) 0.784
IL-8, pg/mL 6.3 (4.6–11.2) 6.4 (4.8–9.5) 6.3 (4.0–13.8) 0.362
IL-6, pg/mL 9.5 (3.5–25.2) 6.2 (2.7–15.5) 21.6 (9.6–28.0) 0.236
IL-6 $ 8.3, n (%) 21 (51) 8 (32) 13 (81) 0.004
Perioperative data
Surgery time, min 325 (270–385) 310 (270–375) 333 (249–390) 0.961
CPB time, min 83 (74–102) 82 (74–107) 84 (71–99) 0.562
ACC time, min 46 (36–56) 49 (36–60) 46 (34–52) 0.436
Data are expressed as median and interquartile range (I-III) or number (percentage).
ACC, aortic cross-clamp; ACEi, angiotensin converting enzyme inhibitor; ATII, angiotensin II receptor antagonists; CI, cardiac index; CPB, cardiopulmonary by-pass; IABP,
intraortic balloon pump; IDC, idiopathic dilated cardiomyopathy; ICM, ischemic cardiomyopathy; INR, International Normalized Ratio; INTERMACS, Interagency Registry
for Mechanically Assisted Circulatory Support; LVEDV, left ventricular end-diastolic volume; LVEDD, left ventricular end-diastolic diameter; LVEF, left ventricular ejection
fraction; MAP, mean arterial pressure; NYHA, New York Heart Association; PCWP, pulmonary capillary wedge pressure; RAP, right atrial pressure; tSOFA, total Sequential
Organ Failure Assessment; WBC, white blood cells count.
doi:10.1371/journal.pone.0090802.t001
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2.0) vs 3.0 (2.6–3.4) L/min/m2 at pre-implant and 1-week post-
LVAD, respectively, p,0.001] and decrease of pulmonary
capillary wedge pressure [26 (18–30) vs 9 (7–11) mmHg at pre-
implant and 1-week post-LVAD, respectively, p,0.001]. Differ-
ently, tSOFA score was significantly increased 1 day after
intervention with respect to pre-implant value (Figure 1), main-
taining higher levels at 3 days and 1 postoperative week. At 2
postoperative weeks, tSOFA score was comparable to preoperative
value (Figure 1).
During ICU stay 8 out of 41 (20%) LVAD-patients died of
MOF, septic shock and esophageal haemorrhage [14 (11–23)
days]. Detailed clinical in-hospital outcomes and primary causes
leading to terminal MOF and death are summarised in Table 2.
Among survivors, the length of ICU stay was of 13 (10–19) days,
while hospitalisation was of 49 (42–77) days. Eight of the survivor
patients experienced severe multi-organ failure evidenced by
postoperative tSOFA score $11, mainly during the first postop-
erative week (Figure 1).
The pre-implant levels of IL-6, IL-8 and Neo/Cr of all LVAD-
candidates were 9.5 (3.5–25.2) pg/mL, 6.3 (4.6–11.2) pg/mL and
290 (183–563) mmol/moL, respectively.
Relationship between pre-implant cytokine levels and
composite adverse outcome
Sixteen of 41 patients (39%) experienced postoperative tSOFA
score $11 and/or ICU-death, together considered as composite
critical outcome. Right heart failure, renal failure and hepatic
dysfunction were the main complications contributing to the
increased postoperative tSOFA score (Table 2).
Among the ROC curve analysis for IL-6, IL-8 and Neo/Cr,
pre-implant IL-6 levels were identified as the only significant
marker for discrimination between patients with or without
composite critical outcome (Figure 2); the ROC curve indicated
an optimal cut-off-point for IL-6 at 8.3 pg/ml, with a sensitivity of
81% and a specificity of 68%.
By univariable analysis, pre-implant plasma IL-6 levels$ 8.3 pg/
ml and right atrial pressure were significantly higher in LVAD-
patients that experienced adverse composite outcome than in
patients without composite outcome (Table 1). The tSOFA score
was higher, but only as a trend, in LVAD-patients that experienced
adverse composite outcome than in patients without composite
outcome (Table 1). Surgery-related variables as well as type of used
devices (not showed in the table) were comparable between groups.
The variables that reached the significance level of p,0.10 were
entered into the final multivariable logistic regression analysis. The
only parameter independently associated with composite outcome
was pre-implant plasma IL-6 levels $ 8.3 pg/ml (OR 6.642, 95%
CI 1.201–36.509, p=0.030).
Patient characteristics according to pre-implant IL-6
levels
Retrospectively, LVAD-candidates were divided in 2 groups
according to pre-implant IL-6 cutoff of 8.3 pg/ml. Twenty
patients with pre-implant IL-6 levels # of 8.3 pg/ml were
assigned to group A [3.5 (1.2–6.1) pg/mL, ranging from 0.4 to
8.3 pg/mL], while the other 21 patients with pre-implant IL-6
levels .8.3 pg/ml were assigned to group B [24.6 (16.4–38.0) pg/
mL, ranging from 9.5 to 500.5 pg/mL]. Pre-implant IL-6 levels of
all LVAD-candidates were higher than those observed in CHF
patients [9.5 (3.5-25.2) and 2.3 (1.5–5.6) pg/mL, respectively,
Figure 1. Postoperative tSOFA profile. Postoperative profile of
tSOFA score in all LVAD-recipients. The tSOFA score $ 11 is pointed out
by a dashed line.
doi:10.1371/journal.pone.0090802.g001
Table 2 Complications and causes of death ‘‘on-LVAD’’
All
Cases
Group
A
Group
B P
(n =41) (n=20) (n =21)
ICU Complications
Need of postoperative IABP 2 (5) 1 (5) 1 (5) 1.000
Bleeding
Requiring surgery 4 (10) 2 (5) 2 (5) 1.000
Requiring . 2 PRBC units 34 (83) 15 (75) 19 (91) 0.238
Hemorrhagic 10 (24) 3 (15) 7 (33) 0.277
Embolism 1 (2) - 1 (5) 1.000
Arrhytmias
Atrial 12 (29) 6 (30) 6 (29) 1.000
Ventricular 4 (10) 1 (5) 3 (14) 0.606
Ventricular tachycardia 4 (10) 1 (5) 3 (14) 0.606
Infection
Sepsis 3 (7) 1 (5) 2 (10) 1.000
Local non device-related
infection
5 (12) 2 (10) 3 (14) 1.000
SIRS 3 (7) - 3 (14) 0.232
Respiratory failure 13 (32) 4 (20) 9 (43) 0.181
Renal failurea 29 (71) 12 (60) 17 (81) 0.181
Hepatic dysfunctionb 25 (61) 9 (45) 16 (76) 0.058
Right heart failure 23 (56) 7 (35) 16 (76) 0.012
Psychological 6 (15) - 6 (29) 0.021
Other neurological 2 (5) 1 (5) 1 (5) 1.000
ICU deaths
MOF 5 (12) 2 (10) 3 (14) 1.000
Esophageal haemorrhage 1 (2) - 1 (5) 1.000
Septic shock 2 (5) - 2 (10) 0.488
Values are presented as number (percentage).
PRBC, packed red blood cells; SIRS, systemic inflammatory response syndrome.
aPost eGFR , 60 ml/min/1.73 m2 or reduction of postoperative eGFR . 25%
with respect to baseline.
bPost total bilirubine . 2 mg/dL and/or postoperative change of total
bilirubine . 0.5 mg/dL with respect to baseline.
doi:10.1371/journal.pone.0090802.t002
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p=0.002], but among LVAD candidates, only patients of group B
showed IL-6 levels significantly higher than CHF patients (p,
0.001). Detailed in-hospital complications and causes of death
between A and B groups are described in Table 2.
The etiology was comparable between 2 groups of LVAD-
candidates defined in according to pre-implant IL-6 cutoff of
8.3 pg/ml (Table 3). Echocardiographic parameters as well as
medical therapies didn’t differ between the groups. Preoperative
values of white blood cells (WBC) and tSOFA score were
significantly higher in B- than in A-group. Among inflammatory
variables, only Neo/Cr levels were higher, but only as a trend, in
patients of B-group than in patients of A-group (Table 3).
The variables that reached the significance level of p,0.10 were
entered into the final multivariable logistic regression analysis. The
only parameter independently associated with pre-implant IL-6
levels higher than 8.3 pg/ml was WBC (OR 1.491, 95% CI
1.004–2.217, p=0.048).
Relationships with tSOFA score at 1 week, ICU stay,
hospitalisation and 3-month survival according to pre-
implant IL-6 levels
Pre-implant levels of cytokines were not significantly correlated
to tSOFA score at 1 week (IL-6: Rs = 0.28, p=0.077; IL-8:
Rs = 0.15, p=0.361; Neo/Cr: Rs = 0.05, p=0.749). However,
patients with pre-implant IL-6 levels .8.3 pg/ml showed higher
tSOFA score at 1 week than patients with pre-implant IL-6 levels
# 8.3 [9 (8–10) and 5 (3–10), respectively, p=0.030].
Among survivors, pre-implant IL-6 and IL-8 levels were
significantly related to the length of ICU stay (IL-6: Rs = 0.52,
p=0.002; IL-8: Rs = 0.38, p=0.028), and post LVAD hospitalisa-
tion (IL-6: Rs = 0.38, p=0.028; IL-8: Rs = 0.42, p=0.016).
Patients with pre-implant IL-6 levels .8.3 pg/ml showed more
prolonged ICU stay and hospitalisation than patients with pre-
implant IL-6 levels # 8.3 (Figure 3), with more frequent
complications, in particular hepatic dysfunction and right heart
failure (Table 2).
The 3-month survival rate was comparable with ICU survival
rate (81%). The frequency of death was higher, although not
significantly, in patients with pre-implant IL-6 levels . 8.3 pg/ml
than patients with pre-implant IL-6 levels # 8.3 [6 (30%) and 2
(10%) died patients, respectively, p=0.238].
Neopterin and cytokine profiles according to pre-implant
IL-6 levels
The Neo/Cr levels progressively increased in both groups after
LVAD implantation, but, at 3 days, Neo/Cr levels were
Figure 2. ROC curves of IL-6, IL-8 and neopterin. Receiver
operating characteristic (ROC) curves of IL-6, IL-8 and Neo/Cr for the
detection of patients with composite critical outcome in the early phase
of LVAD support.
doi:10.1371/journal.pone.0090802.g002
Table 3. Univariable logistic regression analysis of variables
associated to patient group with pre-implant IL-6 . 8.3 pg/
mL.
Group A Group B P
(n = 20) (n =21)
Age, yrs 55 (46–60) 55 (48–64) 0.446
Male gender, n (%) 18 (92) 19 (94) 0.959
Etiology, n (%) 0.164
IDC 10 (50) 15 (71)
ICM 10 (50) 6 (29)
NYHA class, n (%) 0.181
III 9 (43) 4 (20)
IV 12 (57) 16 (80)
INTERMACS, n (%)
1 3 (15) 8 (38) (Reference)
2 6 (30) 3 (14) 0.087
3+4 11 (55) 10 (48) 0.182
LVEF, % 22 (19–24) 20 (18–26) 0.925
LVEDV, ml 235 (185–315) 267 (188–317) 0.777
LVEDD, mm 70 (59–77) 69 (65–78) 0.852
CI, L/min/m2 1.70 (1.36–1.95) 1.67 (1.37–2.10) 0.736
RAP, mmHg 5 (3–9) 6 (5–10) 0.112
PCWP, mmHg 28 (20–33) 25 (16–29) 0.200
MAP, mmHg 75 (68–84) 78 (70–83) 0.789
Treatments, n (%)
ACEi+ATII 15 (79) 14 (70) 0.524
Beta-Blocker 13 (77) 11 (55) 0.179
Statins 7 (41) 5 (25) 0.299
Diuretics 18 (95) 14 (70) 0.072
Inotropic 11 (55) 14 (67) 0.261
Inotropic equivalent, n 8 (2–10) 8 (4–11) 0.468
IABP, n (%) 5 (25) 8 (38) 0.370
INR 1.12 (1.03–1.29) 1.21 (1.14–1.47) 0.292
WBC, 109/L 7.3 (6.1–8.7) 8.7 (7.9–12.0) 0.012
Lactate, nmol/l 1.00 (0.70–1.40) 1.10 (0.78–1.88) 0.192
eGFR, ml/min/1.73 m2 86 (57 –122) 79 (58–92) 0.238
Total bilirubine, mg/dl 0.69 (0.47–1.37) 1.31 (0.62–1.77) 0.115
tSOFA score, n 3.5 (3.0–4.8) 6.0 (4.0–7.0) 0.006
Neo/Cr, mmoL/mol 246 (136–295) 374 (252–693) 0.059
IL-8, pg/mL 6.2 (4.5–7.8) 10.9 (4.9–14.8) 0.088
Data are expressed as median and interquartile range (I-III) or number
(percentage).
Group A: patients with pre-implant IL-6 levels # of 8.3 pg/ml; Group B: patients
with pre-implant IL-6 levels . 8.3 pg/ml. For abbreviations see Table 1.
doi:10.1371/journal.pone.0090802.t003
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significantly higher than baseline only in B-group (p=0.002,
Figure 4A). Moreover, postoperative levels of Neo/Cr were always
higher in B- than in A-group (Figure 4A).
Likewise, also the IL-8 levels showed a progressive increment
after device implantation in both groups compared to baseline
values (Figure 4B); however, postoperative IL-8 levels were always
higher in B- than in A-group (Figure 4B).
Differently, in both groups, the IL-6 profiles showed a peak at 3
days, higher than baseline (p,0.001 and p=0.006 in A- and B-
groups, respectively). In A-group, postoperative IL-6 levels
maintained higher than baseline, also after 7 days and 1 month
(p,0.001, both at 7 days and 1 month), while in B-group, the IL-6
levels at 7 days and 1 month were comparable to the baseline
levels. However, at 1 month, the IL-6 levels were higher in B- than
in A-group (Figure 4C).
Discussion
The main findings of this study may be summarized as follows:
1) ESHF-patients supported by LVAD with preoperative IL-6
levels higher than 8.3 pg/mL are more susceptible of poor early
outcome, longer ICU stay and hospitalisation, when compared to
patients with lower IL-6 levels; 2) postoperatively, LVAD-patients
with IL-6 levels higher than 8.3 pg/mL showed a more
pronounced neopterin and IL-8 release, and MOF severity.
Recent advances in MCS, specifically implantable CF-LVAD
therapy, are providing alternatives for patients waiting for heart
transplantation (HT), for patients who are HT ineligible or
anticipated to experience recovery after LV-unloading [1-4].
Every centre involved in advanced HF treatments has to evaluate
patient specific risk profile according to one’s own experience and
to data reported by larger studies. With worsening of clinical
status, the need for LVAD increases as well as the peri-operative
risk, and optimal operative timing becomes difficult. In this setting,
clinical indications, absolute or relative contraindications are not
universally accepted because of contrasting published data.
With regard to risk stratification in ESHF-patients, little is
known about baseline inflammatory profiles and their impact on
clinical outcome and prognosis, and it’s reasonable to speculate a
role of inflammatory system on the outcome of these fragile
patients. In the present study, pre-implant levels of IL-6, IL-8 and
neopterin were investigated to evaluate the impact of these
monocyte-related inflammatory mediators on the inflammatory
response and outcome in LVAD patients. IL-8, a known
chemokine attracting monocyte on endothelial cells [17], neop-
terin, a pteridine produced by activated macrophages [16], and
IL-6-dependent signals, mainly associated to progression of HF,
are proposed as crucial triggers in controlling monocyte activation
and recruitment in vascular inflammation and endothelial
dysfunction, important factors for development of MOF [10,18].
Moreover, neopterin is a key pteridine that links inflammation and
redox state in heart failure. Indeed macrophages, stimulated by
interferon-gamma, generate neopterin that interferes with reactive
species, such as peroxynitrite, inducing myocardial contractile
failure [19]. However, in our cohort of LVAD-candidates, only
patients with preoperatively elevated IL-6 levels, particularly
higher than 8.3 pg/ml, were more susceptible to experience
serious complications, as severe MOF, with postoperative tSOFA
score $11, and/or death in ICU, independently from IL-8 and
neopterin levels, as well as from the amount of the pre-implant
multi-organ dysfunction. Indeed, in critically ill patients, differ-
ences in mortality have been previously reported to be better
predicted by the maximal t-SOFA score in the first days of ICU
stay; tSOFA score higher than 10 has been associated with
elevated mortality rates [15]. Moreover, in our series, patients with
elevated IL-6 levels were also characterised by a longer ICU stay,
hospitalisation and higher tSOFA score after 1 week, reflecting a
greater disarrangement of multi-organ function than in those with
lower IL-6 levels. Altogether, these data suggest a more critical
clinical course in patients with preoperative elevated IL-6 levels
than in patients with lower IL-6 levels.
The concentration range of IL-6 levels has been found
extremely broad in our LVAD-candidates, ranging from negligible
to extremely pathological values, greater than the highest value
found in CHF patients. These data suggest that in a few ESHF
patients, the hemodynamic collapse requiring LVAD implantation
is associated with increased activation of systemic inflammation,
linked to the IL-6 signals; among preoperative variables, IL-6
levels are associated only with the total leukocyte count, regardless
of the hemodynamic status, as defined by INTERMACS profiles.
Therefore, the evaluation of IL-6 levels in LVAD-candidates may
Figure 3. ICU stay and hospitalisation according to IL-6 levels. Length of ICU stay (A) and hospitalisation (B) in according to pre-implant IL-6
cutoff. A-group (empty box-plots): patients with plasma IL-6 levels#8.3 pg/ml; B-group (dark box-plots): patients with plasma IL-6 levels.8.3 pg/ml.
doi:10.1371/journal.pone.0090802.g003
Role of Pre-Implant Interleukin-6 on LVAD Outcome
PLOS ONE | www.plosone.org 6 March 2014 | Volume 9 | Issue 3 | e90802
provide additional information on patient’s risk profile, in addition
to the prognostic information provided by the INTERMACS
profiles, and could allow to highlight patients more susceptible of
poorer outcome in the early phase of LVAD support, although not
strictly associated to the risk of death. Indeed, in our series of
patients, the pre-implant cut-off-point for IL-6 at 8.3 pg/ml did
not allow to predict survival in the short-time (3 months) of LVAD
support.
Postoperatively, elevated IL-6 levels were reported in patients
who died because of MOF in the early phase of LVAD support,
and the activation of monocytes was proposed as a crucial
mechanism involved in the development of MOF [7]. In a
previous study we reported that, after LVAD implantation,
neopterin levels progressively increased mainly in non-survivors
[6]. In the present cohort, postoperative Neo/Cr and IL-8 levels
increased mainly in patients who showed preoperative IL-6 levels
higher than 8.3 pg/ml, reflecting, postoperatively, a more marked
monocyte activation and adverse inflammatory milieu. Moreover,
postoperative IL-6 levels showed similar profiles in both groups,
with a peak level in the first postoperative days. This finding
supports the hypothesis that only IL-6-dependent inflammatory
signals, present at pre-implant, may be responsible for triggering
stimuli that favor a more marked monocyte activation and adverse
inflammatory milieu after LVAD implantation, as evidenced by
the greater release of IL-8 and neopterin. In addition, the greater
neopterin release in patients with preoperative elevated IL-6 levels
might reflect a more marked pro-oxidant behavior, since neopterin
is also capable of enhancing peroxynitrite production, favoring
LDL oxidation, that exerts chemotactic properties on macrophag-
es [20]. Therefore, different ranges of IL-6 levels in ESHF-patients
needing a LVAD support, might differently affect the redox
processes and immune response to stress stimuli succeeding LVAD
implantation, thus influencing the clinical course and early
outcome.
Kirsh et al. [21] reported that a low percentage of monocytes
expressing HLA-DR molecules, during the immediate phase of
device support, was predictive of ICU-death, suggesting that a low
percentage of HLA-DR positive monocytes reflects a postoperative
immunoparalysis that hampers tissue repair processes necessary
for end-organ recovery. HLA-DR expression is reported as a
phenotypic marker of functional monocyte deactivation, making
controversial clinical interpretation of the monitoring of neopterin
in LVAD-patients. However, the concomitant presence of reduced
proportions of CD14+ HLA-DR cells with elevated levels of
neopterin was reported in trauma patients and sepsis, together
proposed as biomarkers reflecting an immune response, not
balanced, susceptible to favors sepsis and adverse MOF [22–24].
Therefore, the elevated levels of neopterin and IL-8 found in our
Figure 4. Postoperative inflammatory profiles. Postoperative profiles of neopterin (A), IL-8 (B) and IL-6 (C) according to pre-implant IL-6 cutoff
(A-group, empty box-plots; B-group, dark box-plots).
doi:10.1371/journal.pone.0090802.g004
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LVAD-patients with a poorer outcome might reflect an altered
monocyte-mediated immune response, influenced by pre-implant
IL-6 levels.
Our single centre study was limited by its relatively small
number of patients; the results are not related to a single device but
to different CF-LVADs. However, the findings of this study
underscore the importance to consider the inflammatory param-
eters related with monocyte activation during the decision making
process of ESHF-patients, to deepen the knowledge of clinical
features of patients and better stratify the operative risk, and the
risk of MOF or death after LVAD implantation.
Finally, preoperative elevated IL-6 levels, higher than 8.3 pg/
mL, are associated, after intervention, to higher release of markers
related with the monocyte activation, prolonged course and poorer
outcome. Further studies in larger population are needed to
validate the cut-off value of IL-6 and of other potential biomarkers
which could be helpful in targeting the most appropriate
treatment.
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